Association of CYP2B6 Genotype with Survival and Progression Free Survival in Cyclophosphamide Treated Multiple Myeloma

Journals Menu

Follow SCIRP

ISSN Print: 2151-1934
ISSN Online: 2151-1942
www.scirp.org/journal/jct
E-mail: jct@scirp.org

Citations h5-index & Ranking

"Association of CYP2B6 Genotype with Survival and Progression Free Survival in Cyclophosphamide Treated Multiple Myeloma"
written by Ingrid Jakobsen Falk, Muhammad Suleman Khan, Lena Thunell, Hareth Nahi, Henrik Gréen,
published by Journal of Cancer Therapy, Vol.3 No.1, 2012

has been cited by the following article(s):

[1]	Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients
	2021

[2]	CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations—Implication for Drug Safety, Dosing, and Individualized Therapy
	Frontiers in …, 2021

[3]	The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.
	2019

[4]	Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype
	Pharmacology research & perspectives, 2018

[5]	Pharmacogenomics and Chemotherapy
	2015

[6]	The Effects of Ethanol and Nicotine on Hepatic and Brain CYP2 Family Enzymes in African Green Monkeys
	2014

[1]	Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma Scientific Reports, 2023 DOI:10.1038/s41598-023-38983-0

[2]	Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients Cancer Chemotherapy and Pharmacology, 2021 DOI:10.1007/s00280-021-04307-0

[3]	CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations—Implication for Drug Safety, Dosing, and Individualized Therapy Frontiers in Genetics, 2021 DOI:10.3389/fgene.2021.692234

[4]	The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes British Journal of Clinical Pharmacology, 2019 DOI:10.1111/bcp.14031

[5]	The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes British Journal of Clinical Pharmacology, 2019 DOI:10.1111/bcp.14031

[6]	Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype Pharmacology Research & Perspectives, 2018 DOI:10.1002/prp2.419

[7]	Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6 , CYP2B6 , and CYP3A4 genotype Pharmacology Research & Perspectives, 2018 DOI:10.1002/prp2.419

Follow SCIRP